Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00861705?term=NCT00861705&rank=1

2. Intervention

   Carboplatin

3. Intervention

   Bevacizumab

4. Intervention

   Doxorubicin

5. Intervention

   Cyclophosphamide

6. Intervention

   Paclitaxel

7. Intervention

   Antineoplastic combined chemotherapy

8. Resource Description

   This randomized phase II trial is studying how well giving paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery.

9. Additional Name

   Randomized phase II 2 x 2 factorial trial of the addition of carboplatin +/- bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense ACc in hormone receptor-poor/HER2-negative resectable breast cancer

10. Contact

    Berenberg, Jeffrey

11. PI

    Berenberg, Jeffrey

12. Topic

    breast cancer

13. Study Population

    At least 18 years old Stage II or stage IIIA breast cancer Measurable disease HER2-negative, estrogen receptor-negative (ER-), and progesterone receptor-negative (PR-) tumor More than 4 weeks since surgery No previous chemotherapy, hormone therapy, or radiation therapy for this cancer For more information about the eligibility criteria for this trial, refer to the Health Professional version. For more information about the eligibility criteria for this trial, refer to the Health Professional version.

14. Funded by

    Cancer Trials Support Unit

15. Phase

    Phase 2 clinical trial

16. Performed by

    Clinical Protocol & Data Management Shared Resource